Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2021

View Archived Issues

Enrollment opens in phase I study of DCC-3116 in advanced solid tumors with RAS or RAF mutations

First-in-human study of ChAdOx1 RVF vaccine candidate begins at University of Oxford

Origo Biopharma patents TGFBR1 inhibitors

BioNTech initiates first-in-human study of BNT-152 and BNT-153 in solid tumors

Medshine Discovery discloses Chk1 inhibitors for pancreatic cancer

New GTPase KRAS mutant inhibitors presented by Taiho Pharmaceutical

Lunan Pharmaceutical Group describes oleanane cinnamamide derivatives

European researchers identify CaSR-targeting antibodies

City of Hope National Medical Center presents FIH data on COH04S1 vaccine

Promising data reported from CYAD-211 IMMUNICY-1 trial

Initial phase I data on Betalutin in relapsed/refractory DLBCL

Phase II trial of Auxora in patients with acute pancreatitis and accompanying SIRS and hypoxemia

Stimulation of optic nerve activity increases optic glioma growth in mice with Nf1 mutations

Results from first-in-human study of AO-176 in advanced solid tumors

STING inhibitors target inflammatory diseases

Anti-COX-2 Ab is a novel highly specific diagnostic marker in immune aplastic anemia

Sanofi Pasteur and Translate Bio begin phase I trial of mRNA seasonal influenza vaccine

Dicerna begins phase II study of belcesiran for AAT deficiency-associated liver disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.